Biocompatibility and bioavailability studies of a vaginal gel containing hydroxypropyl-beta-cyclodextrin complexes

A tétel rövid nézete
dc.contributor.advisorFenyvesi, Ferenc
dc.contributor.advisordeptGyógyszerésztudományi Kar
dc.contributor.authorTorabi Mousavi, Seyedhadi
dc.contributor.departmentDE--Gyógyszerésztudományi Kar
dc.contributor.opponentHorváth, László
dc.contributor.opponentArany, Petra
dc.contributor.opponentdeptGyógyszerésztudományi Kar
dc.date.accessioned2026-04-13T13:09:15Z
dc.date.available2026-04-13T13:09:15Z
dc.date.created2026-02-11
dc.description.abstractVaginal gels are widely used for the treatment of local vaginal infections, contraception, and the symptoms of menopause. Hormone replacement therapy can be an efficient method for the treatment of menopausal symptoms, and the local application of low-dose estrogen hormones in the vagina improves the safety of the therapy. Our aim is to test an estrogen hormone-containing vaginal gel, which contains estrogens in a hydroxypropyl-betacyclodextrin (HPβCD) complex. Estrogens are insoluble in water; however, their complexation with HPβCD improves its water solubility and bioavailability in the vaginal environment. HPβCD is a widely used cyclic oligosaccharide, improves the solubility of poorly soluble drugs, considered to be safe and non-toxic but the vaginal application of this excipient has not been studied yet. The work aims at testing the vaginal gel on HaCat keratinocyte cell line and SkinEthicTM HVE / Human Vaginal Epithelium model for biocompatibility and toxicity studies. MTT and LDH tests are used for the determination of the toxicity of the gel and its components on the cell line and the vaginal model. The Human Vaginal Epithelium model is also used for determining the amount of estriol permeated through the epithelial cell layers. The effect of the HPβCD -complex on cell proliferation was examined by a wound-healing assay, which may provide new information about the tissue regenerative effects of the complex. The study helps to obtain new data about the safety and efficacy of the vaginal application of HPβCD and its estrogen complex.
dc.description.coursegyógyszerész
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent41
dc.identifier.urihttps://hdl.handle.net/2437/406158
dc.language.isoen
dc.rights.infoHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectBioavailibility, HPBCD, vaginal gel , Estriol
dc.subject.dspaceMedicine::Pharmacology
dc.titleBiocompatibility and bioavailability studies of a vaginal gel containing hydroxypropyl-beta-cyclodextrin complexes
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
Thesis_FINAL.pdf
Méret:
1.15 MB
Formátum:
Adobe Portable Document Format
Leírás:
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Pharmacy)